- Academic Editors
-
-
-
Background: The traditional pathology of adenomyosis (AM) suggests that
this is a common benign uterine disease. Hysterectomy is the gold standard of
care and is viewed as a decisive treatment for AM; however, more conservative
treatment approaches are required to maintain fertility. Unfortunately, there are
few studies focusing on medical treatments for AM. The objective was to
investigate the effect of gonadotropin-releasing hormone agonist (GnRH-a)
combined with dienogest on serum human epididymis secretory protein 4 (HE4) and carbohydrate antigen 125 (CA125) levels in patients with AM and
adenomyoma. Methods: We addressed our objective using a prospective
cohort design. We selected 120 patients treated for AM and adenomyoma from
February 2019 to April 2021 in our hospital. The patients were divided
into a control group and a study group. The control group was treated with GnRH-a
alone, while the study group was treated with GnRH-a combined with dienogest. The
curative effect, dysmenorrhea score, dysmenorrhea grade, serum CA125 and HE4
levels, size of the uterine lesions, and incidence of adverse reactions were
compared between the two groups. Results: When comparing the two groups,
the study group consisted of 43 cases that were significantly effective, 12
effective cases, and five ineffective cases, thus, the effective rate was
91.67%. The control group displayed 23 significantly effective cases, 21
effective cases, and 16 ineffective cases, thus the effective rate for the
control group was 73.33%. The curative effect in the study group was higher than
in the control group, and the difference was statistically significant (p